Neelanjana Sarmah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neelanjana Sarmah has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Biswajyoti Borkakoty
Regional VRDL, Indian Council of Medical Research-Regional Medical Research Centre for NE region (ICMR-RMRC NE), Dibrugarh, 786010, Assam, India
9 shared publications - Aktarul Islam Siddique
Regional VRDL, Indian Council of Medical Research-Regional Medical Research Centre for NE Region (ICMR-RMRC NE), Dibrugarh, Assam, 786010, India
5 shared publications - Nargis K. Bali
Department of Clinical Microbiology, Sher-I Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu & Kashmir, India
5 shared publications - Aniruddha Jakharia
Regional-VRDL, ICMR-Regional Medical Research Centre for NE Region, Dibrugarh, Assam, India
3 shared publications - Basumoti Apum
Bakin Pertin General Hospital & Training Centre, Pasighat, East Siang, Arunachal Pradesh, India
2 shared publications - Chandrakanta Bhattacharya
Regional VRDL, Indian Council of Medical Research-Regional Medical Research Centre for NE Region, Bokel, Dibrugarh, Assam, 786010, India
2 shared publications
Latest Publications
- 11 October 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 65, 101316
Outbreak of BA genotype-derived RSV-B lineages in Northeast India: Molecular epidemiology and phylogenetic insights from Dibrugarh, 2022
- 11 October 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 65, 101316
Outbreak of BA genotype-derived RSV-B lineages in Northeast India: Molecular epidemiology and phylogenetic insights from Dibrugarh, 2022
- 30 April 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 62, 101118
Promoter methylation of APC, P16, and WT1 genes among high-risk HPV infected women of North-Eastern states of India
- 30 April 2026
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 62, 101118
Promoter methylation of APC, P16, and WT1 genes among high-risk HPV infected women of North-Eastern states of India
- 21 November 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 59, 101027
Molecular epidemiology of human rhinovirus from clinical cases of Dibrugarh, Assam, India
- 21 November 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 59, 101027
Molecular epidemiology of human rhinovirus from clinical cases of Dibrugarh, Assam, India
- 25 February 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 54, 100813
Fatal case of Leptospira wolffii infection in Sikkim, India: An autochthonous case from a new geographical region
- 25 February 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 54, 100813
Fatal case of Leptospira wolffii infection in Sikkim, India: An autochthonous case from a new geographical region
- Open Access
- 18 July 2024
- Published by Sri Lanka Journals Online in Sri Lankan Journal of Infectious Diseases
- Vol. 14  (2)
Molecular characterization of Hepatitis C Virus (HCV) from hospitalised cases of hepatitis in six northeastern states of India
Background: Viral hepatitis is of global importance and inflicts a huge healthcare cost in northeast India where its prevalence and the prevalence of drug-resistant variants are not well known. Hepatotropic viruses (hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus) are known to cause âviral hepatitis.â This study documents the prevalence and genotype of Hepatitis C Virus (HCV) in northeast India.Aim: Identification of Hepatitis C Virus (HCV) genotypes with their resistance-associated variants (RAVs) could facilitate the development of selective antiviral drug regimens against HCV infection. The present study aims to identify the HCV genotype from six northeastern states of India.Methods: The study was carried out between 2018-2022 from hospitalised cases of viral hepatitis in six northeastern states of India namely Assam, Meghalaya, Mizoram, Nagaland, Tripura and Manipur. A total of 1300 subjects were enrolled, from whom 88 HCV-positive samples were processed for molecular characterisation.Results: Of the 88 samples evaluated for genotyping and sub-typing, 58 (66%) were HCV genotype 3b, 15 (17%) were 3a, 8 (9 %) were 6n, 2 (2%) were 6xa, 3 (3 %) were 1a, and 2 (2 %) were 1b respectively. Genotype 6n was common among injecting drug users (IDUs) (5/8; 62.5%). Resistance-associated variants (RAVs) 30K and 31M of HCV NS5A region were observed in 5/30 (16.6%) HCV genotype 3b. This could indicate likely resistance to directly acting antivirals (DAAs) targeting the NS5A of HCV. RAVs C316N mutation of NS5B region was also observed in 1/1 (100%) of HCV genotypes 1b.Conclusion: A higher prevalence of HCV genotype 3b was observed in the study population. Furthermore, overlapping of RAVs 30K and 31M of HCV NS5A region with HCV genotype 3b may pose treatment failure. Genotypes HCV 6n and HCV 6xa were also identified, which may be the first to be reported from northeastern parts of India.
- 18 July 2024
- Published by Sri Lanka Journals Online in Sri Lankan Journal of Infectious Diseases
- Vol. 14  (2)
Open AccessMolecular characterization of Hepatitis C Virus (HCV) from hospitalised cases of hepatitis in six northeastern states of India
Background: Viral hepatitis is of global importance and inflicts a huge healthcare cost in northeast India where its prevalence and the prevalence of drug-resistant variants are not well known. Hepatotropic viruses (hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus) are known to cause âviral hepatitis.â This study documents the prevalence and genotype of Hepatitis C Virus (HCV) in northeast India.Aim: Identification of Hepatitis C Virus (HCV) genotypes with their resistance-associated variants (RAVs) could facilitate the development of selective antiviral drug regimens against HCV infection. The present study aims to identify the HCV genotype from six northeastern states of India.Methods: The study was carried out between 2018-2022 from hospitalised cases of viral hepatitis in six northeastern states of India namely Assam, Meghalaya, Mizoram, Nagaland, Tripura and Manipur. A total of 1300 subjects were enrolled, from whom 88 HCV-positive samples were processed for molecular characterisation.Results: Of the 88 samples evaluated for genotyping and sub-typing, 58 (66%) were HCV genotype 3b, 15 (17%) were 3a, 8 (9 %) were 6n, 2 (2%) were 6xa, 3 (3 %) were 1a, and 2 (2 %) were 1b respectively. Genotype 6n was common among injecting drug users (IDUs) (5/8; 62.5%). Resistance-associated variants (RAVs) 30K and 31M of HCV NS5A region were observed in 5/30 (16.6%) HCV genotype 3b. This could indicate likely resistance to directly acting antivirals (DAAs) targeting the NS5A of HCV. RAVs C316N mutation of NS5B region was also observed in 1/1 (100%) of HCV genotypes 1b.Conclusion: A higher prevalence of HCV genotype 3b was observed in the study population. Furthermore, overlapping of RAVs 30K and 31M of HCV NS5A region with HCV genotype 3b may pose treatment failure. Genotypes HCV 6n and HCV 6xa were also identified, which may be the first to be reported from northeastern parts of India.
- 5 March 2024
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 48, 100549
An outbreak of acute hemorrhagic conjunctivitis due to Coxsackievirus A24 in a residential school, Naharlagun, Arunachal Pradesh: July 2023
- 5 March 2024
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 48, 100549
An outbreak of acute hemorrhagic conjunctivitis due to Coxsackievirus A24 in a residential school, Naharlagun, Arunachal Pradesh: July 2023
- Open Access
In Silico Screening of Prospective MHC Class I and II Restricted T-Cell Based Epitopes of the Spike Protein of SARS-CoV-2 for Designing of a Peptide Vaccine for COVID-19
Multiple vaccines were developed and administered to immunize people worldwide against SARS-CoV-2 infection. However, changes in platelet count following the course of vaccination have been reported by many studies, suggesting vaccine-induced thrombocytopenia. In this context, designing an effective targeted subunit vaccine with high specificity and efficiency for people with low platelet counts has become a challenge for researchers. Using the in silico-based approaches and methods, the present study explored the antigenic epitopes of the spike protein of SARS-CoV-2 involved in initial binding of the virus with the angiotensin converting enzyme-2 receptor (ACE-2) on the respiratory epithelial cells. The top ten major histocompatibility complex-I (MHC-I) and MHC-II restricted epitopes were found to have 95.26% and 99.99% HLA-class-I population coverage, respectively. Among the top ten promiscuous MHC-I restricted epitopes, âFTISVTTEIâ had the highest global HLA population coverage of 53.24%, with an antigenic score of 0.85 and a docking score of â162.4 Kcal/mol. The epitope âKLNDLCFTNVâ had the best antigenic score of 2.69 and an HLA population coverage of 43.4% globally. The study predicted and documented the most suitable epitopes with the widest global HLA coverage for synthesis of an efficient peptide-based vaccine against the deadly COVID-19.
Open AccessIn Silico Screening of Prospective MHC Class I and II Restricted T-Cell Based Epitopes of the Spike Protein of SARS-CoV-2 for Designing of a Peptide Vaccine for COVID-19
Multiple vaccines were developed and administered to immunize people worldwide against SARS-CoV-2 infection. However, changes in platelet count following the course of vaccination have been reported by many studies, suggesting vaccine-induced thrombocytopenia. In this context, designing an effective targeted subunit vaccine with high specificity and efficiency for people with low platelet counts has become a challenge for researchers. Using the in silico-based approaches and methods, the present study explored the antigenic epitopes of the spike protein of SARS-CoV-2 involved in initial binding of the virus with the angiotensin converting enzyme-2 receptor (ACE-2) on the respiratory epithelial cells. The top ten major histocompatibility complex-I (MHC-I) and MHC-II restricted epitopes were found to have 95.26% and 99.99% HLA-class-I population coverage, respectively. Among the top ten promiscuous MHC-I restricted epitopes, âFTISVTTEIâ had the highest global HLA population coverage of 53.24%, with an antigenic score of 0.85 and a docking score of â162.4 Kcal/mol. The epitope âKLNDLCFTNVâ had the best antigenic score of 2.69 and an HLA population coverage of 43.4% globally. The study predicted and documented the most suitable epitopes with the widest global HLA coverage for synthesis of an efficient peptide-based vaccine against the deadly COVID-19.
- Open Access
SARS-CoV-2 and Influenza Virus Co-Infection Cases Identified through ILI/SARI Sentinel Surveillance: A Pan-India Report
SARS-CoV-2/influenza virus co-infection studies have focused on hospitalized patients who usually had grave sequelae. Here, we report SARS-CoV-2/influenza virus co-infection cases from both community and hospital settings reported through integrated ILI/SARI (Influenza Like Illness/Severe Acute Respiratory Infection) sentinel surveillance established by the Indian Council of Medical Research. We describe the disease progression and outcomes in these cases. Out of 13,467 samples tested from 4 July 2021â31 January 2022, only 5 (0.04%) were of SARS-CoV-2/influenza virus co-infection from 3 different sites in distinct geographic regions. Of these, three patients with extremes of age required hospital admission, but none required ICU admission or mechanical ventilation. No mortality was reported. The other two co-infection cases from community settings were managed at home. This is the first report on SARS-CoV-2/Influenza virus co-infection from community as well as hospital settings in India and shows that influenza viruses are circulating in the community even during COVID-19. The results emphasize the need for continuous surveillance for multiple respiratory pathogens for effective public health management of ILI/SARI cases in line with the WHO (World Health Organization) recommendations.
Open AccessSARS-CoV-2 and Influenza Virus Co-Infection Cases Identified through ILI/SARI Sentinel Surveillance: A Pan-India Report
SARS-CoV-2/influenza virus co-infection studies have focused on hospitalized patients who usually had grave sequelae. Here, we report SARS-CoV-2/influenza virus co-infection cases from both community and hospital settings reported through integrated ILI/SARI (Influenza Like Illness/Severe Acute Respiratory Infection) sentinel surveillance established by the Indian Council of Medical Research. We describe the disease progression and outcomes in these cases. Out of 13,467 samples tested from 4 July 2021â31 January 2022, only 5 (0.04%) were of SARS-CoV-2/influenza virus co-infection from 3 different sites in distinct geographic regions. Of these, three patients with extremes of age required hospital admission, but none required ICU admission or mechanical ventilation. No mortality was reported. The other two co-infection cases from community settings were managed at home. This is the first report on SARS-CoV-2/Influenza virus co-infection from community as well as hospital settings in India and shows that influenza viruses are circulating in the community even during COVID-19. The results emphasize the need for continuous surveillance for multiple respiratory pathogens for effective public health management of ILI/SARI cases in line with the WHO (World Health Organization) recommendations.
- 2 March 2022
- Published by Elsevier in Human Immunology
- Vol. 83  (5) , 453-457
A comparative study on regulation of HLA-G expression in bad obstetric history and in head and neck squamous cell carcinoma from Northeast India
- 2 March 2022
- Published by Elsevier in Human Immunology
- Vol. 83  (5) , 453-457
A comparative study on regulation of HLA-G expression in bad obstetric history and in head and neck squamous cell carcinoma from Northeast India